口服抗凝药物在瓣膜性心房颤动患者中的应用：来自 NCDR PINNACLE 注册研究的结果。

Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry.

机构信息

Rocky Mountain Regional VA Medical Center, University of Colorado School of Medicine, Aurora, CO.

St. Luke's Mid America Heart Institute, Kansas City, MO.

出版信息

Am Heart J. 2021 Oct;240:58-62. doi: 10.1016/j.ahj.2021.04.017. Epub 2021 May 24.

DOI:10.1016/j.ahj.2021.04.017

PMID:34033802

Abstract

Recent data suggest direct oral anticoagulants are as safe and efficacious as warfarin among select patients with valvular heart disease and atrial fibrillation (AF). However, real-world treatment patterns of AF stroke prophylaxis in the setting of valvular AF are currently unknown. Accordingly, using the prospective, ambulatory National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) Registry, we sought to characterize overall use, temporal trends in use, and the extent of practice-level variation in the use of any direct oral anticoagulant and warfarin among patients with valvular AF from January 1, 2013, to March 31, 2019.

摘要

最近的数据表明，在某些选择的瓣膜性心脏病和心房颤动（AF）患者中，直接口服抗凝剂与华法林一样安全有效。然而，目前尚不清楚在瓣膜性 AF 中，AF 卒中预防的真实世界治疗模式。因此，我们利用前瞻性、门诊的全国心血管数据注册实践创新和临床卓越（PINNACLE）登记处，旨在描述 2013 年 1 月 1 日至 2019 年 3 月 31 日期间，瓣膜性 AF 患者中任何直接口服抗凝剂和华法林的总体使用情况、使用的时间趋势以及实践水平差异的程度。